News

Upcoming data from part C of the DisTinGuish study will further confirm the benefit and safety of DKN-01 in combination with tislelizumab in patients with unresectable, locally advanced or metastatic gastric or gastroesophageal adenocarcinoma.

In the interview, Mark Markowski, MD, discussed how the findings from the phase 1/2 trial of sabizabulin in patients with metastatic castration-resistant prostate cancer this may influence future research with the oral agent.

Visits to the phase 3 FLAMINGO-01 clinical trial sites have been initiated following the lift of a FDA clinical hold.

Orphan drug designation has been granted to NT-I7 by the FDA for patients with glioblastoma multiforme.

Results from the primary analysis of the phase 3 COSMIC-313 trial showed significant improvement in progression-free survival in patients with renal cell carcinoma receiving the combination of cabozantinib, nivolumab, and ipilimumab.

An orphan drug designation and a fast track designation have been granted by the FDA to a novel sonodynamic therapy platform as a potential treatment for patients with recurrent glioblastoma and other malignant gliomas.

In an interview with Targeted Oncology, Matthew T. Campbell, MD, examined the positive phase 1 study results of infigratinib for the treatment of patients with localized upper tract urothelial cancer.

Hispanic and Black men are showing higher cancer-specific mortality rates from HPV-associated throat cancer, and most new cases are being diagnosed in White men at a late-stage.

Remote technology and decentralization tools in cancer clinical trials may be linked to an increase in patient consent rate, according to findings from a cross-sectional study.

Based on findings from the TULIP study, [vic-] trastuzumab duocarmazine may be a new standard treatment option for patients with HER2-positive unresectable locally advanced metastatic breast cancer. a biologics license application has been accepted by the FDA.

Two phase 1/2 trials of IAP0971 and IAE0972 in patients with locally-advanced or metastatic malignant tumors have dosed their first patients.

Orphan drug designation has been granted by the FDA to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors.

In the interview with Targeted Oncology, Marcia S. Brose, MD, PhD, FASCO discussed treatment of TRK fusion-positive thyroid cancer based on the most recent data from 2022 ASCO Annual Meeting and ongoing studies.

In an interview with Targeted Oncology, Anne Wooford, MD, discussed a study of 27 patients with a variety of hematological conditions, unable to find a human leukocyte match donor.

Specific biliary tract cancer clusters have distinct clinical and biologic features which may provide opportunities for therapeutic development.

According to an analysis of 161 trials, patients and physicians should be encouraged to use phase 1 trials for meaningful therapy.

The FDA has granted fast track designation to abelacimab for the treatment of thrombosis associated with cancer. The agent is being assessed in 2 phase 3 clinical trials.

Praluzatamab ravtansine achieved confirmed overall response rate in patients with advanced hormone receptor–positive, HER2-negative breast cancer, meeting the primary end point of the phase 2 CTMX-2009-002 trial.

Gunther Koehne, MD, PhD, discusses his hopes for future advances for patients with hematologic malignancies.

Findings from part A of the phase 2/3 RINGSIDE trial reveal AL102 to demonstrate favorable safety in patients with desmoid tumors.

In an interview with Targeted Oncology, Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis and what will come next for pembrolizumab treatment in renal cell carcinoma.

In an interview with Targeted Oncology, Sam S. Chang, MD, MBA, discussed the background of N-803 plus BCG in patients with BCG-unresponsive non-muscle invasive bladder cancer and what he expects for the future of this space.

In the phase 2 MOUNTAINEER study, the investigational combination of tucatinib and trastuzumab achieved durable response in patients with metastatic colorectal cancer.

Paul G. Richardson, MD, discusses the unmet medical needs that still exist in the multiple myeloma space.

A biologics license application resubmission for toripalimab in combination with gemcitabine and cisplatin and for toripalimab monotherapy has been accepted by the FDA.

Florida Cancer Specialists & Research Institute welcomes Colleen Lewis, MSN, ANP-BC, AOCNP to its senior leadership team as Vice President of Nursing and Research.

The Biden Administration has announced a new model, the Enhancing Oncology Model, aimed at improving cancer care for Medicare and Medicaid patients and lowering health care costs.

Improvement in overall survival has been demonstrated with the combination of durvalumab and tremelimumab in patients with unresectable liver cancer treated in the phase 3 HIMALAYA study.

In the phase 3 TOPAZ-1 trial, the addition of durvalumab to standard-of-care chemotherapy achieved a statistically significant improvement in overall survival compared chemotherapy alone, meeting the study's primary end point.

The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.